Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 7 | 9 |
| 1996 | 3 | 15 | 18 |
| 1997 | 3 | 11 | 14 |
| 1998 | 7 | 18 | 25 |
| 1999 | 7 | 12 | 19 |
| 2000 | 5 | 14 | 19 |
| 2001 | 4 | 21 | 25 |
| 2002 | 16 | 21 | 37 |
| 2003 | 13 | 39 | 52 |
| 2004 | 19 | 30 | 49 |
| 2005 | 25 | 46 | 71 |
| 2006 | 27 | 53 | 80 |
| 2007 | 45 | 60 | 105 |
| 2008 | 42 | 52 | 94 |
| 2009 | 52 | 59 | 111 |
| 2010 | 47 | 75 | 122 |
| 2011 | 57 | 88 | 145 |
| 2012 | 63 | 74 | 137 |
| 2013 | 54 | 58 | 112 |
| 2014 | 55 | 65 | 120 |
| 2015 | 71 | 82 | 153 |
| 2016 | 71 | 76 | 147 |
| 2017 | 59 | 69 | 128 |
| 2018 | 51 | 83 | 134 |
| 2019 | 46 | 82 | 128 |
| 2020 | 50 | 77 | 127 |
| 2021 | 49 | 36 | 85 |
| 2022 | 5 | 26 | 31 |
| 2023 | 8 | 26 | 34 |
| 2024 | 36 | 39 | 75 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Characterization of Persister Cells Provides Insights into Mechanisms of Therapy Resistance in Neuroblastoma. Cancer Discov. 2024 Dec 02; 14(12):2308-2311.
-
BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia. Cells. 2024 Nov 20; 13(22).
-
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations. Expert Rev Hematol. 2024 Dec; 17(12):935-946.
-
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. Clin Cancer Res. 2024 Nov 15; 30(22):5166-5179.
-
Nuclear PD-L1 compartmentalization suppresses tumorigenesis and overcomes immunocheckpoint therapy resistance in mice via histone macroH2A1. J Clin Invest. 2024 Nov 15; 134(22).
-
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024 Nov 01; 14(11):2135-2161.
-
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2024 Nov 01; 14(11):2183-2208.
-
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855.
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
-
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors. Mol Cancer. 2024 Oct 30; 23(1):242.